



D-Dimer, a Biomarker for Diagnosis and Prognosis Assessment of COVID-19

Cheepsattayakorn A^{1,2*}, Cheepsattayakorn R³ and Siriwanarangsun P¹

¹Faculty of Medicine, Western University, Thailand

²10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai University, Thailand

³Department of Pathology, Chiang Mai University, Thailand

***Corresponding author:** Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand, Tel: 6653140767; 6653 276364; Fax: 6653140773; 6653273590; Email: Attapon1958@gmail.com

Editorial

Volume 6 Issue 1

Received Date: October 23, 2021

Published Date: October 28, 2021

DOI: 10.23880/oajprs-16000149

Editorial

Coagulopathy [1] and increased levels of antiphospholipid antibodies [2] are more prevalent in critically ill-COVID-19 patients and may predispose patients to both arterial and venous thrombotic diseases, due to blood circulation stasis, endothelial dysfunction, platelet activation, and excessive inflammation. D-dimer, a marker of fibrinolysis and a proxy for ongoing thrombosis is the sensitive change in coagulation parameters in COVID-19, whereas it has low specificity for the detection of venous thromboembolism [3]. A retrospective cohort study in France demonstrated that D-dimer levels at baseline significantly higher in patients with deep venous thrombosis (DVT) ($p < 0.001$), whereas the positive predictive values for venous thromboembolism (VTE) for baseline D-dimer levels that were equal to $1.0 \mu\text{g}/\text{mL}$ or more and more than $3 \mu\text{g}/\text{mL}$ were 44% and 67%, respectively and the negative predictive values for baseline D-dimer levels that was less than $1.0 \mu\text{g}/\text{mL}$ for VTE and pulmonary embolism (PE) were 90% and 98%, respectively [4]. VTE risk was predicted by elevated D-dimer concentrations of more than $1.0 \mu\text{g}/\text{mL}$ [4]. In another prospective study of 165 consecutive hospitalized-non-intensive-care-unit-COVID-19-related pneumonia patients with D-dimer levels of more than $1,000 \text{ ng}/\text{mL}$ and complete compression doppler ultrasonography screening revealed that the D-dimer levels were higher in diagnosed-DVT patients, compared to other patients ($4,527 \text{ ng}/\text{mL}$ vs. $2,050 \text{ ng}/\text{mL}$; $p < 0.001$) [5]. He, et al. demonstrated that a D-dimer level of $2.025 \text{ mg}/\text{L}$ was the suitable probability cutoff or a prognosis of death, whereas male gender, advanced age, dyspnea, and some underlying diseases were the influencing factors D-dimer levels impacting COVID-19 prognosis [6], whereas Poudel, et al. demonstrated that D-dimer level of $1.5 \mu\text{g}/\text{mL}$ on hospital admission is the

proper cutoff level for predicting the mortality in COVID-19 patients [7]. Zhan, et al. conducted a meta-analysis and meta-regression on diagnostic value of D-dimer levels in COVID-19 patients and revealed that the specificity of the prognostic performance of D-dimer levels for the severity, mortality, and VTE in COVID-19 were 71% (95% CI: 64%-77%), 83% (95% CI: 77%-87%) and 60% (95% CI: 60%-60%), respectively, and the pooled sensitivity were 77% (95% CI: 73%-80%), 75% (95% CI: 65%-82%) and 90% (95% CI: 90%-90%) respectively [8].

In conclusion, D-dimer level testing is not useful for the diagnosis of PE due to low positive predictive values of increased D-dimer levels. The high levels of D-dimer in COVID-19 patients do not definitely making the diagnosis of DVT, but can be used for screening VTE-related-COVID-19. Reduction in D-dimer levels may correlate with COVID-19 clinical improvement.

References

1. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, et al. (2020) Registry of arterial and venous thromboembolic complications in patients with COVID-19. *J Am Coll Cardiol* 76(18): 2060-2072.
2. Devreese KMJ, Linskens EA, Benoit D, Peperstraete H (2020) Antiphospholipid antibodies in patients with COVID-19 : a relevant observation. *J Thromb Haemost* 18 (9): 2191-2201.
3. Righini M, Perrier A, De Moerloose P, Bounameaux H

- (2008) D-dimer for venous thromboembolism diagnosis : 20 years later. *J Thromb Haemost* 6(7): 1059-1071.
4. Artifoni M, Danic G, Gautier G (2020) Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. *J Thromb Thrombolysis* 50 (1): 211-216.
 5. Rodriguez DP, Cervilla-Munnoz E, Ortega OL (2020) Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. *Thromb Res* 192: 23-26.
 6. He X, Yao F, Chen J, Wang Y, Fang X, et al. (2021) The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. *Scientific Reports* 11: 1830.
 7. Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, et al. (2021) D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLoS One* 16(8): e0256744.
 8. Zhan H, Chen H, Liu C, Chen L, Yan S, et al. (2021) Diagnostic value of D-dimer in COVID-19: a meta-analysis and meta-regression. *Clinical and Applied Thrombosis/Hemostasis* 27: 1-10.

